Andrew DeLuise is Co-Founder and Chief Executive Officer of Endurazymes, where he leads the company’s corporate strategy, commercialization, strategic partnerships, and capital formation.
An entrepreneur from the beginning of his career, Andrew developed a passion for building businesses, creating strategic partnerships, and bringing innovative ideas to market. For more than two decades, Andrew has focused on identifying high-potential technologies and building the strategic partnerships, securing the capital, and creating the commercialization pathways needed to bring innovation successfully to market.
He has worked alongside entrepreneurs, research institutions, U.S. national laboratories, investors, and industry leaders to advance emerging technologies through strategic partnerships, technology licensing, business development, and commercialization. At Endurazymes, Andrew is leading the company’s commercialization strategy and helping build the partnerships, capital, and organizational foundation needed to accelerate the adoption of innovative enzyme technologies.
Jeff Wolff serves as Chief Financial Officer of Endurazymes, where he leads the company’s financial strategy, capital planning, and corporate governance. Working closely with the executive leadership team, he helps guide financial decision-making and the disciplined execution that supports the company’s long-term growth.
With more than 25 years of experience across aerospace, defense, intelligent transportation systems, and other high-technology industries, Jeff brings a unique combination of financial leadership, engineering expertise, and analytical problem-solving. His background includes quantitative analysis, financial modeling, systems architecture, software development, and engineering leadership, supporting complex technology programs and initiatives that generated more than $120 million in revenue.
Jeff holds master’s degrees in Business Administration and Computer Science, is a certified Project Management Professional (PMP), and serves as an Adjunct Professor at The George Washington University School of Business. At Endurazymes, he helps ensure the company’s financial strategy and operational discipline support the successful growth and commercialization of its technologies and scientific services.
Thomas Chepucavage serves as Chief Operating Officer of Endurazymes, where he leads operational strategy, organizational execution, and the development of scalable systems that support the company’s long-term growth. He works across the organization to ensure scientific innovation is supported by disciplined execution and operational excellence.
With more than 20 years of experience spanning operations, finance, venture creation, and advanced technology sectors, Thomas has built, funded, and scaled companies focused on deep technology and industrial innovation. His career has been defined by bridging the gap between breakthrough laboratory science and commercial production, helping transform early-stage scientific innovations into scalable commercial enterprises.
His experience includes capital strategy, corporate governance, strategic partnerships, and operational leadership across emerging technology ventures. At Endurazymes, Thomas is helping build the operational foundation that enables the company to scale its technologies, strengthen strategic partnerships, and deliver lasting value to customers and stakeholders.
Anthony Franklin serves as Chief Operating Officer of Endurazymes, where he works across the company’s commercial, operational, and strategic initiatives. He works closely with the executive leadership team to advance strategic partnerships, support commercialization efforts, strengthen internal execution, and help translate company priorities into coordinated action.
With more than 17 years of experience in enterprise software sales, business development, and executive leadership, Anthony has helped technology companies scale through disciplined execution, customer-focused growth strategies, and operational excellence. His background spans SaaS, commercial operations, strategic planning, and growth leadership across founder-led, investor-backed, and high-growth organizations.
Anthony also serves as Managing Principal of Spearhead Capital Partners, where he leads the evaluation, acquisition, and operational growth of technology businesses. At Endurazymes, he brings that same disciplined, market-driven approach to supporting company operations, commercial partnerships, customer adoption, and long-term growth.
Dr. Ross Klauer is Co-Founder and Lead Scientist at Endurazymes. A biochemical engineer and synthetic biologist, his work focuses on enzyme engineering, protein engineering, high-throughput assay development, and translation of scientific discoveries into practical solutions for industrial biotechnology.
His experience bridges academic research, industrial biotechnology, and entrepreneurial innovation, with expertise spanning enzyme discovery, microbial strain engineering, process design, materials science, and industrial catalysis. He has contributed to peer-reviewed scientific publications, patented technologies, and technology development through leading innovation programs, including NSF I-Corps and Nucleate.
At Endurazymes, Ross leads the company’s scientific strategy and technology development, advancing proprietary enzyme screening technologies that help researchers gain earlier insight into enzyme stability, durability, and real-world performance under process-relevant conditions.
Harold Blackwell serves as Chief Strategy Officer of Endurazymes, where he helps guide the company’s long-term strategic direction, corporate development, and growth initiatives. He works closely with the executive leadership team to evaluate strategic opportunities, support capital formation, and position the company for sustainable expansion.
With more than 20 years of experience in strategic finance and capital markets, Harold has advised organizations on mergers and acquisitions, corporate growth strategy, capital formation, and complex financial transactions across defense technology, government services, manufacturing, transportation, and healthcare.
His background includes M&A advisory, private equity transactions, institutional capital relationships, and strategic growth initiatives, working alongside asset managers, hedge funds, private equity firms, and corporate investors. At Endurazymes, Harold helps align strategic planning, financial strategy, and commercial execution to support the company’s long-term vision and continued growth.
Mike Kramer is a Co-Founder of Endurazymes and an experienced technology executive with more than 30 years of leadership experience building, scaling, and transforming companies across enterprise software, AI, cloud technologies, and digital transformation.
Throughout his career, Mike has served as Chief Executive Officer, President, and Chief Revenue Officer for venture-backed, private equity-backed, public, and high-growth technology companies. His experience includes leading go-to-market organizations, driving product commercialization, executing strategic acquisitions and integrations, and supporting multiple successful software company exits.
Mike also serves as Chief Executive Officer of StrataBio, an independent company developing an AI-driven platform designed to leverage scientific and process data to develop predictive intelligence for enzyme discovery and industrial biology.
Mahvash Siddiqui serves as Chief Strategic Affairs Officer & Advisor at Endurazymes, where she helps guide the company’s international strategy, government engagement, and strategic partnerships. Drawing on more than 22 years as a career U.S. diplomat and a technical foundation in genetic engineering and biotechnology, she helps navigate the geopolitical, regulatory, and commercial considerations associated with bringing advanced technologies to global markets.
Throughout her diplomatic career, Mahvash held leadership roles across Europe, the Middle East, South Asia, and the Pacific, culminating in her service as Acting U.S. Ambassador (Chargé d’Affaires) to the Kingdom of Tonga. She played a key role in high-level international science and technology negotiations, including the U.S.-China Science and Technology Agreement, while working closely with agencies such as the NSF, NIH, DOE, USDA, DoD, and other U.S. government organizations.
At Endurazymes, Mahvash helps strengthen the company’s global strategy by supporting international partnerships, regulatory engagement, technology commercialization, and public-private collaboration. Her unique combination of scientific training, diplomatic leadership, and international policy experience helps position Endurazymes for responsible global growth and long-term strategic success.
Scott Warden serves as Chief Business Officer of Endurazymes, where he leads business development, capital formation, strategic partnerships, and commercial growth initiatives. He works closely with the company’s leadership team to help expand industry relationships, support financing activities, and advance the commercialization of Endurazymes’ technologies.
With extensive experience in capital markets and financial services, Scott has built a career focused on connecting innovative companies with investors, strategic partners, and growth opportunities. His background includes capital formation, investment advisory, securities, alternative investments, and relationship management, providing a strong foundation for supporting emerging technology companies as they scale.
At Endurazymes, Scott helps strengthen the company’s commercial strategy by fostering relationships with investors, industry partners, and stakeholders who share the vision of accelerating innovation in industrial biotechnology.
Mark Gehrett serves as Vice President of Growth & Strategic Partnerships at Endurazymes, where he leads initiatives that expand strategic relationships, support market growth, and accelerate the adoption of the company’s technologies and scientific services. He works closely with customers, partners, and the executive leadership team to identify opportunities that strengthen Endurazymes’ position across industrial biotechnology and related markets.
Mark brings extensive leadership experience in enterprise technology, industrial automation, AI, and emerging technologies. Throughout his career, he has held leadership roles with Hewlett Packard, Samsung Electronics, and Overhead Door Corporation, where he focused on product strategy, go-to-market execution, strategic partnerships, and market expansion.
At Endurazymes, Mark helps translate scientific innovation into commercial opportunity by building strategic partnerships, expanding market engagement, and supporting the long-term growth of the company’s technologies and scientific services.
Douglas leads corporate development initiatives focused on strategic growth, corporate partnerships, and expanding commercial opportunities. He also helps build awareness of the company’s technologies and scientific capabilities through industry engagement and strategic relationship development.
With more than 30 years of executive leadership experience, Doug has led business development and growth initiatives across multiple industries. His background spans strategic planning, market development, corporate partnerships, and building relationships that create long-term commercial value.
Corey Park is the Founder of Endurazymes and a technology entrepreneur with more than 30 years of experience building and advancing innovation-driven companies. His career has focused on identifying breakthrough technologies originating from universities and U.S. government laboratories and helping transform early-stage scientific discoveries into commercially viable businesses.
Throughout his career, Corey has led the formation and growth of multiple ventures, including companies that have reached the public markets and others that have been successfully acquired. His experience spans technology evaluation, commercialization strategy, capital formation, and the development of strategic partnerships, including licensing, sponsored research, and joint ventures.
As Founder of Endurazymes, Corey helped establish the company’s vision of accelerating enzyme discovery by providing researchers and industrial partners with earlier insight into real-world enzyme performance. He continues to support the company’s long-term strategic direction, technology commercialization efforts, and key institutional relationships.
Robert Long serves as Executive Vice President, Operations & Administration of Endurazymes, where he supports the company’s strategic planning, corporate administration, governance, and operational execution. He works across the organization to help translate company priorities into coordinated action and support the infrastructure required for growth.
His background includes business development, commercialization, go-to-market strategy, and introducing technology-driven products to new markets. Throughout his career, Robert has worked across commercial, strategic, and operational functions to help growing organizations develop the processes and relationships needed to execute effectively.
At Endurazymes, Robert works closely with the executive leadership team on corporate governance, strategic initiatives, organizational development, and the administrative and operational matters that support the company’s continued growth.
Satish Kumar Sirimalla serves as Director of Web Systems & Digital Infrastructure at Endurazymes, where he leads the development and management of the company’s website, digital communications, and web-based systems. His work helps ensure that Endurazymes maintains a professional, secure, and reliable digital presence that supports customer engagement, business operations, and organizational growth.
With more than 20 years of experience in technology leadership, Satish has designed, built, and managed enterprise web systems that support organizations through scalable digital solutions. His background includes website architecture, systems integration, web technologies, and the implementation of reliable digital platforms across a variety of business environments.
At Endurazymes, Satish helps strengthen the company’s digital presence by developing the web systems and communication tools that support collaboration, stakeholder engagement, and the organization’s continued growth.
Sophia Tremari is Development Scientist at Endurazymes, where she supports scientific development, laboratory operations, and the advancement of technologies designed to improve enzyme discovery and real-world performance. Her work helps bridge scientific research, product development, and commercialization within regulated environments.
Her background includes scientific development, pharmaceutical research, and regulatory operations, with experience supporting compliant product development, documentation systems, pharmacovigilance, and quality processes across regulated industries. She has worked with multidisciplinary teams to ensure development activities remain aligned with regulatory requirements throughout the product lifecycle.
At Endurazymes, Sophia contributes to the development of the company’s scientific technologies by combining laboratory expertise with a strong understanding of quality systems and regulatory expectations. Her work helps support the translation of innovative research into reliable, commercially relevant solutions.
Laura Miller supports People & Organizational Development at Endurazymes, helping build the organizational foundation that supports the company’s long-term growth. She works closely with the leadership team to strengthen leadership development, organizational effectiveness, and internal collaboration as the company continues to scale.
Her background includes organizational development, team development, organizational design, and internal communications within technology-driven environments. She has supported initiatives that improve organizational structure, strengthen cross-functional collaboration, and align people strategies with business objectives.
At Endurazymes, Laura is focused on helping build a high-performing organization by fostering leadership development, effective communication, and a collaborative culture that enables innovation, accountability, and sustainable growth.
Dr. Nick Poulios serves as Senior Advisor, Clinical Strategy & Outcomes at Endurazymes, where he provides strategic guidance on product value, evidence development, market access, and commercialization within regulated industries. His experience helps the company evaluate opportunities where scientific innovation intersects with clinical, regulatory, and commercial considerations.
With more than 35 years of experience spanning pharmaceuticals, molecular diagnostics, biotechnology, and clinical research, Dr. Poulios has held global leadership positions with Roche, Baxter, Elan, Wyeth, and Biogen. He founded and led the Medical Outcomes Research and Economics (MORE) organization at Roche, helping shape global strategies for product value, clinical outcomes, pricing, reimbursement, and market access.
At Endurazymes, Dr. Poulios provides strategic insight that helps align scientific innovation with long-term commercial value. His expertise in evidence generation, product positioning, and healthcare economics strengthens the company’s ability to evaluate future opportunities in regulated and evidence-driven markets.
Rob Haywood serves as Strategic Advisor to Endurazymes, where he provides guidance on organizational growth, operational strategy, and business execution. He works closely with the leadership team to help align strategic initiatives with the practical execution required to support long-term growth.
With experience advising private equity-backed, growth-stage, and technology-driven companies, Rob has supported organizations through periods of expansion, operational improvement, and organizational development. His background includes strategic planning, commercialization support, operational optimization, and helping leadership teams build scalable business practices.
At Endurazymes, Rob provides strategic insight that helps strengthen organizational alignment, improve execution, and support the company’s continued growth as it advances its technologies and scientific services.